NCI 5611: PHASE II STUDY OF BEVACIZUMAB (RHUMAB-VEGF) IN HEPATOCELLULAR CANCER

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目的是：(1)确定贝伐单抗在不可切除的肝癌（肿瘤未侵犯门静脉主干或转移）患者中的疗效和安全性；(2)收集肿瘤血管灌注动力学信息，通过动态钆增强MRI确定，在贝伐单抗治疗前后；(3)收集与HCC发病有关的VEGF及相关细胞因子的循环水平，以及VEGF抑制下这些水平可能发生的变化；(4)收集肝硬化患者肝功能和肝炎病毒活性的信息，以及VEGF抑制的潜在改变

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims are: (1) to determine efficacy and safety of bevacizumab in patients with unresectable hepatocellular cancer (without tumor invasion of main portal vein or metastasis); (2) to collect information on tumor vascular perfusion kinetics, as determined by dynamic gadolinium-enhanced MRI, before and following bevacizumab therapy; (3) to collect information circulating levels of VEGF and related cytokines which also contribute to HCC pathogenesis and on potential alterations of these levels in the setting of VEGF-inhibition; and (4) to collect information on hepatic function and hepatitis viral activity in cirrhosis and upon potential alterations in the setting of VEGF inhibit